Buy, Sell or Hold: Novo-Nordisk (NVO-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Novo-Nordisk (NVO-N)

NYSE:NVO

158.05

1.40 (0.88%) 1d

WEAK BUY

Traditionally, insulin. Now into weight loss, big home run, stock has charged ahead. Up 40%. Only one approved by the FDA, the leader. Stock won't go down as long as sales keep up. Market is massive. See his Top Picks.

biotechnology / pharmaceutical

BUY

Has owned this for 20 years. They specialize in diabetes meds. They now have developed a weight-loss drug; shares have surged a lot in the past year given huge demand. NOVO can invest their cash flow into more R&D of drugs.

biotechnology / pharmaceutical

BUY

Top supplier of insulin. A very good company. Their diabetes drug has sold out so shares have plateaued. That said, he prefers Eli Lilly.

biotechnology / pharmaceutical

COMMENT

The stock is up so much, but they produce the right medical products.

biotechnology / pharmaceutical

BUY

Likes company and has owned shares for a long time. #1 company in European diabetic market. Share prices are a little over priced. Will continue holding shares for the long term.

biotechnology / pharmaceutical

WEAK BUY

NVO vs. LLY Focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Feb 10/21, Up 46%) Believes company is leading insulin producer for diabetics. Revenues outside USA are increasing. Above average financial results from previous quarter was rewarded by market. Rising diabetes levels in society will be good for company. Company has very little debt and is looking at other products.

biotechnology / pharmaceutical

COMMENT

He was negative on this 5 years ago but now likes it and owns some for the long term. Insulin prices have normalized and it has a good weight loss drug. When asked to compare to Lilly he prefers NVO although Lilly is good too. The only concern is that this is a defensive growth stock and some might sell to buy cyclicals.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Feb 10/21, Up 49%) Leading company for making insulin. The FDA approved their 2.5mg dose of weight-loss drug, which helped share prices. They are first to market with it. The expectations for earnings were moved higher. Getting more international sales in the long term. Stock is starting to get noticed by fund managers internationally.

biotechnology / pharmaceutical

BUY

A Danish drug company that makes insulin. He likes the pharma stocks, though have been underperforming. He owns many pharmas, but you can't own all of them.

biotechnology / pharmaceutical

HOLD

Largest producer of insulin in the world. Diabetes is one of the fastest-growing diseases. Will continue to do well.

biotechnology / pharmaceutical

TOP PICK

A long time favourite. Recent news was FDA approval of a diabetes drug that can also be used for weight-loss. (Analysts’ price target is $76.50)

biotechnology / pharmaceutical

TOP PICK

Take a pill once a week instead of injecting. Big implications moving forward. International sales have gone beyond what US sales were. Good entry point for the next 5-10 years. May get more diversified over time. No debt outstanding. Yield is 1.45% (Analysts’ price target is $75.73)

biotechnology / pharmaceutical

COMMENT

It's focused 90% in diabetes products which offers a competitive advantage. He owned this before, but sold it because its options liquidity is low in the US (he trades options). Instead, he owns its direct competitor, Eli Lily, which boasts more product diversity. (Both companies have phase 3 Covid drugs.) Novo is a leader in diabetes and good to own unless you trade options.

biotechnology / pharmaceutical

BUY

The largest maker of insulin in the world. They have a strong diabetes franchise. Type diabetes is growing incredibly quickly around the world. They are one of the few companies that are involved in Diabetes. He thinks it will continue to accelerate and why this one will do well. It is a great story at 21 times earnings and 2% dividend yield. He will continue to buy it.

biotechnology / pharmaceutical

Showing 1 to 15 of 101 entries

«
‹
1
2
3
4
5
›
»

Next Page

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 4 stock analysts published opinions about NVO-N. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

4 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2023-06-09, Novo-Nordisk (NVO-N) stock closed at a price of $158.05.

You may also like:

RAR-X APQ-T QXM-T BAN-T RES-T AVT-Q PRPL-Q MGNI-Q BEC-N EVLLF-O

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.